Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.

Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.

Disclosed are a food composition containing 2′-fucosyllactose and a pharmaceutical composition containing 2′-fucosyllactose that are effective in ameliorating, preventing or treating various cerebrovascular diseases caused by thrombogenesis, and a method for ameliorating a cerebrovascular disease caused by a thrombus by administering a composition including 2′-fucosyllactose (2′-FL) to a subject in need thereof. The 2′-fucosyllactose (2′-FL) exhibits antagonistic (inhibitory) activity against CRP and collagen, which are agonists of platelets, and thus can be used to inhibit thrombogenesis due to abnormal platelet activity.

A method for producing at least one microneedle containing a vaccine for transdermal delivery of the vaccine to a patient includes preparing microparticles or nanoparticles of encapsulated vaccine by preparing a solution comprising a vaccine antigen and a biocompatible polymer matrix; and spray drying the solution to form the microparticles or nanoparticles. The method includes the further steps of preparing a film composition including at least one pre-polymer solution; preparing a suspension comprising the microparticles or nanoparticles and the film composition; loading the suspension into a 3D printer; printing, via the 3D printer, at least one microneedle made from the suspension; and, converting the pre-polymer solution into a cross-linked biopolymer by exposing the at least one microneedle to UV light. Also disclosed are microneedles containing a vaccine for transdermal delivery.

A method for producing at least one microneedle containing a vaccine for transdermal delivery of the vaccine to a patient includes preparing microparticles or nanoparticles of encapsulated vaccine by preparing a solution comprising a vaccine antigen and a biocompatible polymer matrix; and spray drying the solution to form the microparticles or nanoparticles. The method includes the further steps of preparing a film composition including at least one pre-polymer solution; preparing a suspension comprising the microparticles or nanoparticles and the film composition; loading the suspension into a 3D printer; printing, via the 3D printer, at least one microneedle made from the suspension; and, converting the pre-polymer solution into a cross-linked biopolymer by exposing the at least one microneedle to UV light. Also disclosed are microneedles containing a vaccine for transdermal delivery.

A pharmaceutical paste formulation containing an active ingredient, an API solubilizer, a cross-linking agent, a consistency improver, a rheology modifier, a humectant, and a liquid base.

A pharmaceutical paste formulation containing an active ingredient, an API solubilizer, a cross-linking agent, a consistency improver, a rheology modifier, a humectant, and a liquid base.

Disclosed is a method for preventing or treating muscular atrophy or sarcopenia, the method comprising administering a composition comprising 2′-fucosyllactose (2′-FL) as an active ingredient to a subject in need thereof. The composition administered to the subject increases the expression of genes related to mitochondrial function enhancement and mitochondrial biosynthesis, and reduces the expression of atrogin-1 and MuRF1 genes, which are markers for muscular atrophy, thereby providing effects of strengthening muscles and preventing muscular atrophy or sarcopenia.

A method of promoting bone health in a moderately malnourished individual is provided. The method includes treating the moderately malnourished individual with a nutritional composition that contains a carbohydrate blend. The carbohydrate blend includes a source of at least one carbohydrate that provides rapidly available glucose, a source of at least one carbohydrate that provides slowly available glucose, and a source of at least one non-digestible carbohydrate or resistant starch.

A method of promoting bone health in a moderately malnourished individual is provided. The method includes treating the moderately malnourished individual with a nutritional composition that contains a carbohydrate blend. The carbohydrate blend includes a source of at least one carbohydrate that provides rapidly available glucose, a source of at least one carbohydrate that provides slowly available glucose, and a source of at least one non-digestible carbohydrate or resistant starch.